Literature DB >> 19325492

Predicting cancer-control outcomes in patients with renal cell carcinoma.

Hendrik Isbarn1, Pierre I Karakiewicz.   

Abstract

PURPOSE OF REVIEW: An increasing number of models are becoming available for patients with either suspected or established renal cell carcinoma (RCC) of various stages. In this review, we propose a systematic approach to the assessment of the quantity of the existing predictive and prognostic models. RECENT
FINDINGS: Only one model was designed to distinguish between malignant or benign histology prior to nephrectomy and another tool attempts to discriminate between low-grade and high-grade histology. Four tools predict the natural history of RCC using preoperative tumor characteristics. Postnephrectomy recurrence can be predicted with four tools. Finally, mortality predictions can be quantified with 21 predictive tools. Although several of these tools are validated, formal tests were performed in surprisingly few such models.
SUMMARY: Multiple models can be applied to nephrectomy candidates, to patients treated with nephrectomy, or to individuals with metastatic RCC regardless of nephrectomy status. For newly diagnosed and untreated patients, these tools can guide the clinician with respect to treatment selection. For patients treated with nephrectomy, they can assess the risk of recurrence and/or mortality and can guide the type and frequency of follow-up considerations. Finally, for patients with metastatic RCC, the models can provide the best estimate of remaining life expectancy. Unfortunately, virtually no data are available to model the prognosis of patients subjected to surveillance or nonextirpative treatment models.

Entities:  

Mesh:

Year:  2009        PMID: 19325492     DOI: 10.1097/MOU.0b013e32832a0814

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  8 in total

1.  Pathological characteristics and radiographic correlates of complex renal cysts.

Authors:  Adam C Reese; Pamela T Johnson; Michael A Gorin; Phillip M Pierorazio; Mohamad E Allaf; Elliot K Fishman; George J Netto; Christian P Pavlovich
Journal:  Urol Oncol       Date:  2014-07-09       Impact factor: 3.498

Review 2.  Prognostic factors in renal cell carcinoma.

Authors:  Alessandro Volpe; Jean Jacques Patard
Journal:  World J Urol       Date:  2010-04-03       Impact factor: 4.226

Review 3.  Renal cell carcinoma: where will the state-of-the-art lead us?

Authors:  A Rose Brannon; W Kimryn Rathmell
Journal:  Curr Oncol Rep       Date:  2010-05       Impact factor: 5.075

Review 4.  Prognostic and Predictive Factors for Renal Cell Carcinoma.

Authors:  Cristina Suárez; Marc Campayo; Romà Bastús; Sergi Castillo; Olatz Etxanitz; Marta Guix; Núria Sala; Enrique Gallardo
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 5.  Predictive models for the practical management of renal cell carcinoma.

Authors:  Lui Shiong Lee; Min-Han Tan
Journal:  Nat Rev Urol       Date:  2012-01-10       Impact factor: 14.432

6.  Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio.

Authors:  Kyo Chul Koo; Kwang Suk Lee; Kang Su Cho; Koon Ho Rha; Sung Joon Hong; Byung Ha Chung
Journal:  Int Urol Nephrol       Date:  2016-03-05       Impact factor: 2.370

Review 7.  Serum and urine biomarkers for human renal cell carcinoma.

Authors:  A L Pastore; G Palleschi; L Silvestri; D Moschese; S Ricci; V Petrozza; A Carbone; A Di Carlo
Journal:  Dis Markers       Date:  2015-04-02       Impact factor: 3.434

8.  Prediction of Incontinence after Robot-Assisted Radical Prostatectomy: Development and Validation of a 24-Month Incontinence Nomogram.

Authors:  Ruben M Pinkhasov; Timothy Lee; Rogerio Huang; Bonnie Berkley; Alexandr M Pinkhasov; Nicole Dodge; Matthew S Loecher; Gaybrielle James; Elena Pop; Kristopher Attwood; James L Mohler
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.